{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-025172","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2026-05-26T12:30:22+00:00","discovered_at":"2026-05-26T12:35:03.485223+00:00","generated_at":"2026-05-26T12:35:14.545916+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"confidence":"high","headline":"Cocrystal Pharma announces discovery of pan-viral inhibitors with <50 nM potency against hantavirus","bullets":["Novel pan-viral inhibitors target L-protein of Andes hantavirus; IC50 <50 nM against hantaan virus in vitro.","Company expanding platform from CDI-988 (Phase 1b norovirus) to hantavirus, bunyavirus, influenza.","No approved treatments or vaccines for hantaviruses; Andes strain linked to recent cruise ship outbreak with 3 deaths.","Plans to evaluate activity against Andes hantavirus replication enzyme and explore partnerships."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025172","json":"https://secwatch.observer/filing/0001493152-26-025172.json","markdown":"https://secwatch.observer/filing/0001493152-26-025172.md","text":"https://secwatch.observer/filing/0001493152-26-025172.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226025172/0001493152-26-025172-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226025172/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T12:35:14.545916+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}